MBX Biosciences, Inc. Common Stock
Financials
Valuation Metrics
MBX Biosciences, Inc. Common Stock's Market Cap is $2.99B. At end of 2025 it was $1.15B. Ranked #1717 of 3,121 in US market (top 55%), #617 of 1,463 on NASDAQ (top 42%), #105 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 39%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.99B | US#1,717/3,121 Sec#105/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-104M | US—/3,121 Sec—/266 |
| Total Assets | $436M | US#2,820/3,121 Sec#177/266 |
| Net Assets | $410M | US#2,365/3,121 Sec#131/266 |
| Employees | 63 | US#2,689/3,121 Sec#200/266 |
| Value | ||
| P/B | 7.31x | US#2,474/3,121 Sec#175/266 |
| FCF Yield | -2.85% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -25.47% | US#2,537/3,121 Sec#106/266 |
| ROA | -23.93% | US#2,842/3,121 Sec#140/266 |
| Financial Health | ||
| Debt Ratio | 6.44% | US#57/3,121 Sec#26/266 |
| Total Debt | $3M | US#2,940/3,121 Sec#227/266 |
| FCF | $-85M | US#2,609/3,121 Sec#133/266 |
| Cash | $54M | US#2,553/3,121 Sec#224/266 |
| Current Ratio | 18.08x | US#132/3,121 Sec#33/266 |
| Performance | ||
| 1Y Return | 524.73% | US#7/3,121 Sec#5/266 |
| 1M Return | -8.03% | US#1,540/3,121 Sec#132/266 |
| From 52W High | -13.39% | US#890/3,121 Sec#60/266 |
| 1Y MDD | -35.51% | US#1,770/3,121 Sec#117/266 |
| Trading | ||
| Volume | 764,644 shares | US#1,436/3,121 Sec#153/266 |
| Trading Value | $48M | US#1,134/3,121 Sec#84/266 |
| Per Share | ||
| EPS | $-2.19 | US—/3,121 Sec—/266 |
| BPS | $8.60 | US#1,941/3,121 Sec#80/266 |
Company Info
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.